In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

SHIFT: Reduction in hospitalization for worsening of heart failure with ivabradine in patients with chronic systolic heart failure in the SHIFT trial

Heart Failure (HF)


Presenter: Jeffrey Stephen Borer | see Discussant report



List of Authors: Jeffrey S Borer,1 Michael Böhm,2 Ian Ford,3 Michel Komajda,4 Luigi Tavazzi,5, Jose Lopez Sendon,6 Marco Alings,7 Esteban Lopez-de-Sa,6 and Karl Swedberg,8
on behalf of the SHIFT Investigators



We explored the effect of treatment with ivabradine, a pure heart rate–slowing agent, on recurrent hospitalizations for worsening heart failure (HF) in the SHIFT trial.

Methods and results:
SHIFT was a double-blind clinical trial in which 6505 patients with moderate-to-severe HF and left ventricular systolic dysfunction, all of whom had been hospitalized for HF during the preceding year, were randomized to ivabradine or to placebo on a background of guideline recommended HF therapy (including maximized beta-blockade). In total, 1186 patients experienced at least one additional HF hospitalization during the study, 472 suffered at least two, and 218 suffered at least three. Patients with additional HF hospitalizations had more severe disease than those without. Ivabradine was associated with fewer total HF hospitalizations (902 events versus 1211 events with placebo; incidence rate ratio, 0.75, 95% CI, 0.65 to 0.87, p=0.0002) during the 22.9-month median follow-up. Ivabradine-treated patients evidenced lower risk for a second or third additional HF hospitalization (HR, 0.66, 95% CI, 0.55 to 0.79, p<0.001 and HR, 0.71, 95% CI, 0.54 to 0.93, p=0.012, respectively). Similar observations were made for all-cause and cardiovascular hospitalizations.

Treatment with ivabradine, on a background of guidelines-based HF therapy, is associated with a substantial reduction in the likelihood of recurrent hospitalizations for worsening HF. This benefit can be expected to reduce the burden of HF for the patient and to substantially reduce health care costs.

Discussant: Stefan Anker | see Presenter abstract




710001 - 710002


Clinical Trial & Registry Update II: Updates on Heart Failure and Coronary Artery Disease

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.